Maquet CV: Old Name, New Emerging Mid-Cap Strategic Acquirer
Executive Summary
After some recent changes – like moving its headquarters to the US and spending $2.3 billion on several recent deals – Maquet is becoming just what the cardiovascular device industry needs: a mid-sized company committed to an aggressive acquisition strategy.
You may also be interested in...
Getinge/Maquet CV Emerging As Mid-Cap Strategic With Atrium Acquisition
At a time when the cardiovascular device industry is seeing less interest in M&A on the part of several large strategic players that formerly were major acquirers, a new mid-cap player appears to be emerging: Getinge's Maquet Cardiovascular division. The company recently announced its third major cardiovascular deal in the last five years with its $680 million acquisition of Hudson, NH-based Atrium Medical, which has a diversified cardiovascular products business.
Turning That Frown Upside Down: Treating Depression With Facial Botox Injections
In this episode of the In Vivo podcast, Eric Finzi, CEO of Healis Therapeutics, discusses how his company is targeting major depression, post-traumatic stress disorder and other mental illnesses using facial botox injections.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.